No absolutes
D Hackam - CMAJ, 2003 - Can Med Assoc
Daniel Hackam1 recently summarized the results of a primary prevention trial with lipid-
lowering therapy. 2 However, these results suffer from a limitation of many reports of …
lowering therapy. 2 However, these results suffer from a limitation of many reports of …
Selections from current literature: the fight over fat: is pharmacological lipid lowering useful for coronary primary prevention?
L Green - Family practice, 1997 - academic.oup.com
The optimistic bias favouring intervention in medicine has long been known, and it may be
fair to say that compensating for this characteristic tendency of human judgement is a …
fair to say that compensating for this characteristic tendency of human judgement is a …
Primary prevention of cardiovascular disease: time to get more or less personal?
AD Hingorani, BM Psaty - Jama, 2009 - jamanetwork.com
IN THE 1980S, ROSE COINED THE TERM PREVENTION PARA-dox to describe the fact
that a large proportion of car-diovascular disease (CVD) events occur among the many …
that a large proportion of car-diovascular disease (CVD) events occur among the many …
Letter by Kelland and Roberts Regarding Article,“Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required”
NF Kelland, AP Roberts - Circulation, 2008 - Am Heart Assoc
We agree with Drs Superko and King that only by fully appreciating the differences between
relative and absolute risk reduction can we determine the best treatment for our patients. 1 …
relative and absolute risk reduction can we determine the best treatment for our patients. 1 …
The Great Debate of 2008—How Low to Go in Preventive Cardiology?
ED Peterson, TY Wang - JAMA, 2008 - jamanetwork.com
THE DEBATES OF 2008 HAVE ALREADY BEEN QUITE IN-tense. During this election year,
politicians and pun-dits alike, reviewing the same set of information, have formulated …
politicians and pun-dits alike, reviewing the same set of information, have formulated …
Risk reduction
V Fuster, AM Gotto Jr - Circulation, 2000 - Am Heart Assoc
In the 1950s, atherosclerosis, the disease process underlying coronary heart disease
(CHD), was considered an inevitable, irreversible, and degenerative consequence of aging …
(CHD), was considered an inevitable, irreversible, and degenerative consequence of aging …
[CITATION][C] Section III Discussion
Dr. Bilheimer: It seems the faculty is agreed that endpoint trials are indeed required for every
potentially new member of a class of low-density lipoprotein (LDL)-lowering drugs. However …
potentially new member of a class of low-density lipoprotein (LDL)-lowering drugs. However …
Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?
AM Gotto Jr, LH Kuller - Circulation, 2002 - Am Heart Assoc
Discussion In this study, the overall increase in eligibility is encouraging and consistent with
our expectations. However, we should consider that the sample was selected largely on the …
our expectations. However, we should consider that the sample was selected largely on the …
Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial—Reply
JR Downs, AM Gotto Jr, M Clearfield, S Weis - JAMA, 1999 - jamanetwork.com
To the Editor: The Air Force/Texas Coronary Atherosclerosis Prevention Study
(AFCAPS/TexCAPS) provides further evidence on the benefit of statin treatment for primary …
(AFCAPS/TexCAPS) provides further evidence on the benefit of statin treatment for primary …
Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial—Reply
RS Rosenson, CC Tangney - JAMA, 1999 - jamanetwork.com
To the Editor: The Air Force/Texas Coronary Atherosclerosis Prevention Study
(AFCAPS/TexCAPS) provides further evidence on the benefit of statin treatment for primary …
(AFCAPS/TexCAPS) provides further evidence on the benefit of statin treatment for primary …
